| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Journal of Lipid Research, Vol 33, 755-763, Copyright © 1992 by Lipid Research, Inc.
ARTICLES |
DJ Rader, RE Gregg, MS Meng, JR Schaefer, LA Zech, MD Benson and HB Brewer Jr
Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
Apolipoprotein (apo) A-I is the major protein constituent of plasma high density lipoproteins (HDL). A kindred has been identified in which a glycine to arginine mutation at residue 26 in apoA-I is associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. We isolated the mutant protein, termed apoA-IIowa, from the plasma of an affected subject and studied its in vivo metabolism compared to that of normal apoA-I in two heterozygous apoA-IIowa subjects and two normal controls. Normal and mutant apoA-I were radioiodinated with 131I and 125I, respectively, reassociated with autologous plasma lipoproteins, and simultaneously injected into all subjects. Kinetic analysis of the plasma radioactivity curves demonstrated that the mutant apoA-IIowa was rapidly cleared from plasma (mean fractional catabolic rate [FCR] 0.559 day-1) compared with normal apoA-I (mean FCR 0.244 day-1) in all four subjects. The FCR of normal apoA-I was also substantially faster in the heterozygous apoA-IIowa subjects (mean FCR 0.281 days-1) than in the normal controls (mean FCR 0.203 days-1). Despite the rapid removal from plasma of apoA-IIowa, the cumulative urinary excretion of its associated radioactivity after 2 weeks (44%) of the injected dose) was substantially less than that associated with normal apoA-I (78% of injected dose), indicating extravascular sequestration of radiolabeled apoA-IIowa.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Rashid, B. W. Patterson, and G. F. Lewis Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans? J. Lipid Res., August 1, 2006; 47(8): 1631 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Hovingh, A. Brownlie, R. J. Bisoendial, M. P. Dube, J. H.M. Levels, W. Petersen, R. P.F. Dullaart, E. S.G. Stroes, A. H. Zwinderman, E. de Groot, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1429 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Parolini, G. Chiesa, Y. Zhu, T. Forte, S. Caligari, E. Gianazza, M. G. Sacco, C. R. Sirtori, and E. M. Rubin Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-IMilano. EVIDENCE OF APOA-IM IMPAIRED HEPATIC SECRETION J. Biol. Chem., February 7, 2003; 278(7): 4740 - 4746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mangione, M. Sunde, S. Giorgetti, M. Stoppini, G. Esposito, L. Gianelli, L. Obici, L. Asti, A. Andreola, P. Viglino, et al. Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure Protein Sci., January 1, 2001; 10(1): 187 - 199. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. M. de Sousa, C. Vital, D. Ostler, R. Fernandes, J. Pouget-Abadie, D. Carles, and M. J. Saraiva Apolipoprotein AI and Transthyretin as Components of Amyloid Fibrils in a Kindred with apoAI Leu178His Amyloidosis Am. J. Pathol., June 1, 2000; 156(6): 1911 - 1917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Obici, V. Bellotti, P. Mangione, M. Stoppini, E. Arbustini, L. Verga, I. Zorzoli, E. Anesi, G. Zanotti, C. Campana, et al. The New Apolipoprotein A-I Variant Leu174 -> Ser Causes Hereditary Cardiac Amyloidosis, and the Amyloid Fibrils Are Constituted by the 93-Residue N-Terminal Polypeptide Am. J. Pathol., September 1, 1999; 155(3): 695 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Han, J. Sasaki, A. Matsunaga, H. Hakamata, W. Huang, M. Ageta, T. Taguchi, T. Koga, M. Kugi, S. Horiuchi, et al. A Novel Mutant, ApoA-I Nichinan (Glu235->0), Is Associated With Low HDL Cholesterol Levels and Decreased Cholesterol Efflux From Cells Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1447 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Walsh A Novel Amyloidogenic Variant of Apolipoprotein AI : Implications for a Conformational Change Leading to Cardiomyopathy Am. J. Pathol., January 1, 1999; 154(1): 11 - 14. [Full Text] [PDF]
|
|
|
|
|
|
L. Hamidi Asl, J. J. Liepnieks, K. Hamidi Asl, T. Uemichi, G. Moulin, E. Desjoyaux, R. Loire, M. Delpech, G. Grateau, and M. D. Benson Hereditary Amyloid Cardiomyopathy Caused by a Variant Apolipoprotein A1 Am. J. Pathol., January 1, 1999; 154(1): 221 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Miller, D. Aiello, H. Pritchard, G. Friel, and K. Zeller Apolipoprotein A-IZavalla (Leu159->Pro) : HDL Cholesterol Deficiency in a Kindred Associated With Premature Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., August 1, 1998; 18(8): 1242 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Batal, M. Tremblay, L. Krimbou, O. Mamer, J. Davignon, J. Genest Jr, and J. S. Cohn Familial HDL Deficiency Characterized by Hypercatabolism of Mature ApoA-I but Not ProApoA-I Arterioscler. Thromb. Vasc. Biol., April 1, 1998; 18(4): 655 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Huang, J. Sasaki, A. Matsunaga, H. Nanimatsu, K. Moriyama, H. Han, M. Kugi, T. Koga, K. Yamaguchi, and K. Arakawa A Novel Homozygous Missense Mutation in the Apo A-I Gene With Apo A-I Deficiency Arterioscler. Thromb. Vasc. Biol., March 1, 1998; 18(3): 389 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hamidi Asl, J. J. Liepnieks, T. Uemichi, J.-M. Rebibou, E. Justrabo, D. Droz, C. Mousson, J.-M. Chalopin, M. D. Benson, M. Delpech, et al. Renal Amyloidosis With a Frame Shift Mutation in Fibrinogen Aalpha -Chain Gene Producing a Novel Amyloid Protein Blood, December 15, 1997; 90(12): 4799 - 4805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Miettinen, M. Jauhiainen, H. Gylling, S. Ehnholm, A. Palomaki, T. A. Miettinen, and K. Kontula Apolipoprotein A-IFIN (Leu159->Arg) Mutation Affects Lecithin : Cholesterol Acyltransferase Activation and Subclass Distribution of HDL but Not Cholesterol Efflux From Fibroblasts Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3021 - 3032. [Abstract] [Full Text]
|
|
|
|
|
|
M. Tilly-Kiesi, A. H. Lichtenstein, J. M. Ordovas, G. Dolnikowski, R. Malmstrom, M.-R. Taskinen, and E. J. Schaefer Subjects With ApoA-I(Lys107->0) Exhibit Enhanced Fractional Catabolic Rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI With AII) Arterioscler. Thromb. Vasc. Biol., May 1, 1997; 17(5): 873 - 880. [Abstract] [Full Text]
|
|
|
|
|
|
H. E. Miettinen, H. Gylling, T. A. Miettinen, J. Viikari, L. Paulin, and K. Kontula Apolipoprotein A-IFin: Dominantly Inherited Hypoalphalipoproteinemia Due to a Single Base Substitution in the Apolipoprotein A-I Gene Arterioscler. Thromb. Vasc. Biol., January 1, 1997; 17(1): 83 - 90. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Miccoli, A. Bertolotto, R. Navalesi, L. Odoguardi, A. Boni, J. Wessling, H. Funke, H. Wiebusch, A. von Eckardstein, and G. Assmann Compound Heterozygosity for a Structural Apolipoprotein A-I Variant, Apo A-I(L141R)Pisa, and an Apolipoprotein A-I Null Allele in Patients With Absence of HDL Cholesterol, Corneal Opacifications, and Coronary Heart Disease Circulation, October 1, 1996; 94(7): 1622 - 1628. [Abstract] [Full Text]
|
|
|
|
|
|
P. Holvoet, Z. Zhao, E. Deridder, A. Dhoest, and D. Collen Effects of Deletion of the Carboxyl-terminal Domain of ApoA-I or of Its Substitution with Helices of ApoA-II on in Vitro and in Vivo Lipoprotein Association J. Biol. Chem., August 9, 1996; 271(32): 19395 - 19401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tilly-Kiesi, Z. Qiuping, S. Ehnholm, J. Kahri, S. Lahdenpera, C. Ehnholm, and M.-R. Taskinen ApoA-IHelsinki (Lys107->0) Associated With Reduced HDL Cholesterol and LpA-I:A-II Deficiency Arterioscler. Thromb. Vasc. Biol., September 1, 1995; 15(9): 1294 - 1306. [Abstract] [Full Text]
|
|
|
|
|
|
M. Marcil, B. Boucher, L. Krimbou, B. C. Solymoss, J. Davignon, J. Frohlich, and J. Genest Jr Severe Familial HDL Deficiency in French-Canadian Kindreds : Clinical, Biochemical, and Molecular Characterization Arterioscler. Thromb. Vasc. Biol., August 1, 1995; 15(8): 1015 - 1024. [Abstract] [Full Text]
|
|
|
|
|
|
H. H.-J. Schmidt, A. T. Remaley, J. A. Stonik, R. Ronan, A. Wellmann, F. Thomas, L. A. Zech, H. B. Brewer Jr., and J. M. Hoeg Carboxyl-terminal Domain Truncation Alters Apolipoprotein A-I in Vivo Catabolism J. Biol. Chem., March 10, 1995; 270(10): 5469 - 5475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Scott, D. C. McManus, V. Franklin, A. G. McKenzie, T. Neville, D. L. Sparks, and Y. L. Marcel The N-terminal Globular Domain and the First Class A Amphipathic Helix of Apolipoprotein A-I Are Important for Lecithin:Cholesterol Acyltransferase Activation and the Maturation of High Density Lipoprotein in Vivo J. Biol. Chem., December 21, 2001; 276(52): 48716 - 48724. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
